Imaavy’s approval is based on data from the pivotal Vivacity-MG3 trial. It demonstrated that the antibody with standard of care (SOC) significantly improved disease control over 24 weeks against ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label ...

The FDA's decision was based on the phase III Vivacity-MG3 study and its ongoing open-label extension. The primary endpoint in Vivacity-MG3 was the change in Myasthenia Gravis Activities of Daily ...

Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMG a score in ...

1 The approval of the FcRn-blocking monoclonal antibody, which works by reducing immunoglobulin G (IgG), was supported by data from the ongoing Vivacity-MG3 study. Nipocalimab joins a roster of ...